NUVL vs. ALPN, MDGL, PRGO, ALKS, INSM, CRNX, SMMT, BHVN, AXSM, and BBIO
Should you be buying Nuvalent stock or one of its competitors? The main competitors of Nuvalent include Alpine Immune Sciences (ALPN), Madrigal Pharmaceuticals (MDGL), Perrigo (PRGO), Alkermes (ALKS), Insmed (INSM), Crinetics Pharmaceuticals (CRNX), Summit Therapeutics (SMMT), Biohaven (BHVN), Axsome Therapeutics (AXSM), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical preparations" industry.
Nuvalent (NASDAQ:NUVL) and Alpine Immune Sciences (NASDAQ:ALPN) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, community ranking, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.
Nuvalent currently has a consensus price target of $90.78, suggesting a potential upside of 38.63%. Alpine Immune Sciences has a consensus price target of $50.33, suggesting a potential downside of 22.49%. Given Nuvalent's stronger consensus rating and higher probable upside, equities research analysts plainly believe Nuvalent is more favorable than Alpine Immune Sciences.
97.3% of Nuvalent shares are held by institutional investors. Comparatively, 75.2% of Alpine Immune Sciences shares are held by institutional investors. 14.8% of Nuvalent shares are held by company insiders. Comparatively, 42.3% of Alpine Immune Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, Nuvalent had 2 more articles in the media than Alpine Immune Sciences. MarketBeat recorded 13 mentions for Nuvalent and 11 mentions for Alpine Immune Sciences. Alpine Immune Sciences' average media sentiment score of 1.48 beat Nuvalent's score of 0.28 indicating that Alpine Immune Sciences is being referred to more favorably in the news media.
Alpine Immune Sciences received 355 more outperform votes than Nuvalent when rated by MarketBeat users. However, 70.59% of users gave Nuvalent an outperform vote while only 64.57% of users gave Alpine Immune Sciences an outperform vote.
Nuvalent has a beta of 1.35, meaning that its share price is 35% more volatile than the S&P 500. Comparatively, Alpine Immune Sciences has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500.
Alpine Immune Sciences has higher revenue and earnings than Nuvalent. Alpine Immune Sciences is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks.
Nuvalent has a net margin of 0.00% compared to Alpine Immune Sciences' net margin of -65.17%. Alpine Immune Sciences' return on equity of -16.77% beat Nuvalent's return on equity.
Summary
Nuvalent beats Alpine Immune Sciences on 9 of the 17 factors compared between the two stocks.
Get Nuvalent News Delivered to You Automatically
Sign up to receive the latest news and ratings for NUVL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NUVL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nuvalent Competitors List
Related Companies and Tools
